Case Report: Pembrolizumab unmasks a capillary leak syndrome with chylothorax in early TNBC

Pembrolizumab has become standard of care in early-stage triple-negative breast cancer (TNBC), but its expanding use may induce rare adverse events involving vascular and lymphatic endothelium. Capillary leak syndrome (CLS) remains an exceptionally rare toxicity of PD-1 blockade, scarcely reported i...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Naïla Benkalfate, Ghazi Hadjamara, Caroline Petorin, Magaly Zappa, Aimable Habonimana, Dufens Pierre Louis, Anne-Laure Chene, Jean-Patrick Clarke, Renan Liberge, Kinane Drak Alsibai, Claire Defrance, Barbara Pistilli, Baptiste Boulet, Soraya Benguerfi, Houari Aissaoui
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2026-05-01
סדרה:	Frontiers in Oncology
נושאים:	capillary leak syndrome (CLS) chylothorax immune-related adverse event (irAE) pembrolizumab triple-negative breast cancer (TNBC)
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1786343/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!